Pulmonary metastasis from colorectal carcinoma with hepatic metastasis

被引：10

作者：

Tsukioka T. ^{[1
]}

Nishiyama N. ^{[1
]}

Iwata T. ^{[1
]}

Nagano K. ^{[1
]}

Izumi N. ^{[1
]}

Mizuguchi S. ^{[1
]}

Morita R. ^{[1
]}

Inoue K. ^{[1
]}

Suehiro S. ^{[1
]}

机构：

[1] Department of Thoracic Surgery, Osaka City University Hospital, Abeno-ku, Osaka 545-8586

来源：

General Thoracic and Cardiovascular Surgery | 2007年 / 55卷 / 11期

关键词：

Chemotherapy; Colorectal carcinoma; Hepatic metastasis; Pulmonary metastasis; Surgical treatment;

D O I：

10.1007/s11748-007-0165-z

中图分类号：

学科分类号：

摘要：

Objective. Although some beneficial effects of surgical treatments for pulmonary or hepatic metastases from colorectal carcinoma have been reported, identifying candidates for these aggressive surgical procedures is controversial. In this study, patients with pulmonary metastases from colorectal carcinoma, particularly those with pulmonary and hepatic metastases, were retrospectively analyzed. Methods. Forty-six patients who had undergone complete resection for pulmonary metastases from colorectal carcinoma were retrospectively analyzed. Results. The median follow-up period after pulmonary resection was 26 months, and the 5-year postoperative survival rate was 34%. The 5- and 10-year survival rates of patients with pulmonary metastasis alone, metachronous pulmonary metastasis after liver metastasis, and synchronous metastasis to the liver and lung were 75%, 75%, and 25% and 25%, 38%, and 0%, respectively, when calculated from the time of primary colorectal resection (P < 0.01). Patients with synchronous metastases had a poorer prognosis than did the patients in the other two groups. Conclusions. Surgical treatments for patients with pulmonary metastasis alone or metachronous metastasis can provide a beneficial outcome. Patients with synchronous metastasis have a poor prognosis, and effective pre- and postoperative systemic treatments should be considered to prolong their survival. © 2007 The Japanese Association for Thoracic Surgery.

引用

页码：455 / 460

页数：5

共 13 条

[1]

Iizasa T., Suzuki M., Yoshida S., Motohashi S., Yasufuku K., Iyoda A., Et al., Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer, Ann Thorac Surg, 82, pp. 254-60, (2006)

[2]

Inoue M., Ohta M., Iuchi K., Matsumura A., Ideguchi K., Yasumitsu T., Et al., Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma, Ann Thorac Surg, 78, pp. 238-44, (2004)

[3]

Okumura S., Kondo H., Tsuboi M., Nakayama H., Asamura H., Tsuchiya R., Et al., Pulmonary resection for metastatic colorectal cancer: Experiences with 159 patients, J Thorac Cardiovasc Surg, 112, pp. 867-74, (1996)

[4]

Thomford N.R., Woolner L.B., Clagett T., The surgical treatment of metastatic tumors in the lung, J Thorac Cardiovasc Surg, 49, pp. 357-63, (1965)

[5]

Robinson B.J., Rice T.W., Strong S.A., Rybicki L.A., Blackstone E.H., Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer?, J Thorac Cardiovasc Surg, 117, pp. 66-75, (1999)

[6]

Kobayashi K., Kawamura M., Ishihara T., Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer, J Thorac Cardiovasc Surg, 118, pp. 1090-6, (1999)

[7]

Patel N.A., Keenan R.J., Medich D.S., Woo Y., Celebrezze J., Santucci T., Et al., The presence of colorectal hepatic metastases does not preclude pulmonary metastasectomy, Am Surg, 69, pp. 1047-53, (2003)

[8]

Andre T., Louvet C., Maindrault-Goebel F., Couteau C., Mabro M., Lotz J.P., Et al., CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR, Eur J Cancer, 35, pp. 1343-7, (1999)

[9]

De Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Et al., Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 18, pp. 2938-47, (2000)

[10]

Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Et al., FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study, J Clin Oncol, 22, pp. 229-37, (2004)

← 1 2 →